U.S. FDA approved the first targeted medicine for the treatment of patients with relapsed or refractory pediatric low-grade glioma – Day One Biopharmaceuticals
Day One Biopharmaceuticals shared a post on LinkedIn:
“Breaking News: Today, we are thrilled to share the accelerated approval by the U.S. FDA of the first targeted medicine for the treatment of patients with relapsed or refractory pediatric low-grade glioma (pLGG) with a BRAF fusion or rearrangement, or BRAF V600 mutation. We are grateful to the patients who participated in our clinical trial and their families who supported them, as well as the support of the many members of the pLGG community who helped make this achievement possible.”
Source: Day One Biopharmaceuticals/LinkedIn
About OncoDaily
OncoDaily was founded in 2023. It is a US-based oncology media platform, which features the latest news, insights, and patient stories from the world of oncology. Within short period of time it became one of the leading oncology media platforms globally.
OncoDaily gathers content from various sources, including social media posts from renowned oncologists from all over the world, news from oncology societies and cancer centers, patient and survivor stories, and career-related information for professionals.
The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”